Seelos Therapeutics, Inc. Cash Flow Conversion Efficiency
Seelos Therapeutics, Inc. cash flow conversion efficiency. Based on the latest financial reports, Seelos Therapeutics, Inc. (SEELQ) has a cash flow conversion efficiency ratio of 0.035x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-972.00K) by net assets ($-28.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Seelos Therapeutics, Inc. (2020–2023)
Cash flow conversion efficiency of Seelos Therapeutics, Inc. from 2020 to 2023. This chart illustrates how Seelos Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View SEELQ share price today for real-time trading data and today's change.
Seelos Therapeutics, Inc. Cash Flow Conversion Ratio Explained
Seelos Therapeutics, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Seelos Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Seelos Therapeutics, Inc. ranked by their cash flow conversion efficiency. Also see Seelos Therapeutics, Inc. stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nuvve Holding Corp
NASDAQ:NVVEW
|
2.691x |
|
Jack Nathan Medical Corp
V:JNH
|
0.214x |
|
RPCG PCL F
F:R4Q
|
0.061x |
|
Innoviz Technologies Ltd
NASDAQ:INVZW
|
-0.153x |
|
Godha Cabcon & Insulation Limited
NSE:GODHA
|
-1.064x |
|
Solartron Public Company Limited
F:TUUF
|
0.037x |
|
Advantage Solutions Inc
NASDAQ:ADVWW
|
0.090x |
|
Katapult Holdings Equity Warrants Exp 09 June 2026
NASDAQ:KPLTW
|
-3.039x |
Annual Cash Flow Conversion Efficiency for Seelos Therapeutics, Inc. (2020–2023)
The table below shows the annual cash flow conversion efficiency of Seelos Therapeutics, Inc. from 2020 to 2023. Review Seelos Therapeutics, Inc. (SEELQ) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-33.51 Million | $-23.91 Million | 0.714x | -87.71% |
| 2022-12-31 | $-10.61 Million | $-61.60 Million | 5.806x | +779.25% |
| 2021-12-31 | $57.32 Million | $-48.99 Million | -0.855x | +89.49% |
| 2020-12-31 | $2.57 Million | $-20.91 Million | -8.131x | -- |
About Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therap… Read more